AMOEBA (EPA:ALMIB) - Amoéba: DE SANGOSSE GROUP IS EVALUATING AMOEBA'S BIOCONTROL PRODUCTS

Transparency directive : regulatory news

18/03/2020 17:45

PRESS RELEASE

DE SANGOSSE GROUP IS EVALUATING AMOEBA'S BIOCONTROL PRODUCTS.

Chassieu (France), March 18, 2020 - AMOEBA (FR0011051598 - AMEBA), producer of
a biological biocide capable of eliminating the risk in water and human wounds,
and of a biocontrol product for plant protection, still in the testing phase,
announces the signature of a Material Transfer Agreement with the DE SANGOSSE
group. This partnership with an international player in crop protection, plant
nutrition and pest control aims at extending the performance evaluation of
biocontrol products containing the active substance of Amoeba: the amoeba
lysate Willaertia magna C2c Maky.

As the French leader in biosolutions, the DE SANGOSSE group is particularly
interested in substances of natural origin and wants to test products
containing the active substance of Amoéba as a fungicide.

The purpose of this research partnership is the delivery by Amoéba of
experimental products containing the amoeba lysate Willaertia magna C2c Maky.
In return, the DE SANGOSSE group will carry out its own field trials in order
to evaluate the performance of these products in preventing essential diseases
of cereals, potatoes, apples and beet.

Amoéba and DE SANGOSSE are thus beginning a targeted research phase which, if
successful, could promote the commercial development of Amoéba's biocontrol
solutions.

"In line with our BioSolutions strategy, DE SANGOSSE wanted to test Amoéba's
innovation in 2020 in order to measure its technical and economic potential. On
this basis, DE SANGOSSE could envisage the continued development of this
project with Amoéba in the years to come" indicates Nicolas Fillon, Managing
Director of DE SANGOSSE.

"A closer relationship with the major players in crop protection is part of
Amoéba's development strategy for its biocontrol activity. These trials have a
significant potential for the company to add value and are an essential step
towards a possible commercial partnership," explains Fabrice Plasson, CEO of
Amoéba

Amoéba recalls that the company is still in the testing phase for its biocide
and biocontrol applications and does not currently market any product.

About DE SANGOSSE
DE SANGOSSE (Agen - France) is a French company that innovates, manufactures
and markets products on the Plant Protection and Nutrition and Pest Control
markets. The group's mission is to provide high-performance technical solutions
and a high level of expertise to its customers in its strategic fields of
activity. The DE SANGOSSE range of products is regularly enriched by new
innovations thanks to significant investments allocated to Research and
Development. The group's approach is to promote modern, productive and
environmentally friendly agriculture. DE SANGOSSE has a turnover of 280 MEUR
and employs 850 people worldwide. The majority of DE SANGOSSE's equity is held
by its employees, which guarantees its independence and ensures a long-term
vision of the business project.

Contacts:

Nicolas FILLON
Directeur Général
06 46 23 70 79
fillonn@desangosse.com

Christophe ZUGAJ
Responsable Communication
06 16 54 92 47
zugajc@desangosse.com

About AMOEBA:
Amoéba's ambition is to become a major player in the treatment of bacterial
risk in the fields of water, healthcare and plant protection. Our biological
solution is an alternative to chemical products widely used today. Amoéba is
currently focusing on the market of industrial cooling towers estimated at
EUR1.7Bn (1) on a global chemical biocide market for water treatment, evaluated
at EUR21Bn (2) and on the biocontrol market for plant protection estimated
globally at EUR1.6Bn (4). In the future, the Company is looking at developing
new applications such as chronic wound care, estimated at EUR 751 million (3)
in the USA. Sales of associated products with healthcare, biocides and crop
protection are subject to the Company being granted local regulatory market
authorizations. The Company is currently in a trial phase for biocidal and
plant protection applications and does not market any products.
Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada
and in the United States, Amoéba is quoted on the compartment C of Euronext
Paris. The Company is a member of the BPIfrance Excellence network and is
eligible for the PEA-PME SME equity savings plan setup. More information on
www.amoeba-biocide.com. (1): Amoéba data combined from sources: DRIRE 2013,
Eurostat, ARHIA 2013
(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et
MarketsandMarkets
(3): BCC Research, "Markets for Advanced Wound Management Technologies,"
Wellesley, MA, 2017
(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts:

Amoéba
Valérie FILIATRE
Directeur Général Adjoint
04 26 69 16 00
valerie.filiatre@amoeba-biocide.com

Calyptus
Relations investisseurs & Presse
Grégory BOSSON / Mathieu CALLEUX
01 53 65 37 90 /91
amoeba@calyptus.net

Disclaimer

This press release contains certain forward-looking statements concerning
AMOEBA which are based on its own assumptions and hypothesis and on information
that are available to us. However, AMOEBA gives no assurance that the estimates
contained in such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the reference
document of AMOEBA filed with the French Financial Markets Authority (Autorité
des Marchés Financiers) on April 25, 2019 under number D19-0383 (a copy of
which is available on www.amoeba-biocide.com). The forward-looking statements
contained in this press release are also subject to risks not yet known to
AMOEBA or not currently considered material by AMOEBA. The occurrence of all or
part of such risks could cause actual results, financial conditions,
performance or achievements of AMOEBA to be materially different from such
forward-looking statements.

AMOEBA's latest news

28/03/2024 18:30

AMOEBA (EPA:ALMIB) - Amoéba: DE SANGOSSE GROUP IS EVALUATING AMOEBA'S BIOCONTROL PRODUCTS

Transparency directive : regulatory news

AMOEBA's latest news

Other stories